Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook

Key Takeaways NVO shares slumped 15% after a conservative outlook pointed to a 5-13% sales decline in 2026. Novo Nordisk cited U.S. pricing pressure and semaglutide patent expiries as key drags. NVO highlighted new U.S. leadership and wider Wegovy rollout, boosting appeal of diversified ETFs. Shares of Danish drugmaker Novo Nordisk (NVO) suffered a sharp slump of 15% on the bourses on Tuesday, after the company issued a conservative sales outlook that implied a 5-13% decline in 2026 from last year. This new ...